Susan E. Burwig, Executive Vice President of Operations at Medpace Holdings, Inc., filed a statement of changes in beneficial ownership on October 28, 2026, reporting a series of open-market sales and an option exercise transacted on October 26 and 27, 2026.

Key Highlights

  • Shares sold: Burwig disposed of a total of 20,000 shares of Medpace Holdings common stock across two dates, 16,060 on October 26 and 3,940 on October 27, 2026, each at a price of $677 per share.
  • Option exercise: Burwig exercised an employee stock option for 328 shares of common stock on October 26, 2026, at an exercise price of $166.73 per share.
  • Option background: According to the filing, the exercised option vested in full on October 27, 2025, and carried an expiration date of October 27, 2026.
  • Remaining ownership: Following all reported transactions, Burwig directly held 54,012 shares of Medpace Holdings common stock.
  • Transaction basis: The filing states that the sales were effected pursuant to a limit order placed by Burwig during an open window period.
  • Signed by proxy: The filing was signed by Stephen P. Ewald as Attorney-in-Fact for Susan E. Burwig on October 28, 2026.

Burwig's October Transactions in Medpace Holdings Common Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) is a clinical contract research organization that provides scientific and regulatory services to the pharmaceutical, biotechnology, and medical device industries. Susan E. Burwig, serving as Executive Vice President of Operations, reported three separate transactions in the company's common stock during the two-day period ending October 27, 2026, according to the filing.

On October 26, 2026, Burwig disposed of 16,060 shares at $677 per share and simultaneously exercised an employee stock option covering 328 shares at an exercise price of $166.73, acquiring those shares directly. The filing notes that this option had vested in full on October 27, 2025, and was set to expire on October 27, 2026. The price of the derivative security at exercise was reported as $0. On October 27, 2026, Burwig sold an additional 3,940 shares, also at $677 per share, bringing total dispositions over the two days to 20,000 shares. Both sale transactions were carried out under a limit order placed during an open window period, as disclosed in the filing's explanation of responses.

After all transactions were completed, Burwig's direct beneficial ownership stood at 54,012 shares of Medpace Holdings common stock, with no indirect holdings reported. No derivative securities remained held following the option exercise, as the filing records zero derivative securities beneficially owned after the transaction.

What Was Disclosed

The filing disclosed two open-market sales totaling 20,000 shares at $677 each, one employee stock option exercise of 328 shares at $166.73, and a resulting direct beneficial ownership of 54,012 shares of Medpace Holdings common stock, all transacted on October 26 and 27, 2026.